Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CAMKK1 | Q8N5S9 | 2/20 | 0.34 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | LPL | P06858 | 3/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29548599 | 0.85 | IRAK4 (0.35) | IRAK4PIK3CA | |
| SCHEMBL31394806 | 0.79 | IRAK4 (0.46) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL31387118 | 0.78 | IRAK4 (0.43) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL22551943 | 0.75 | IRAK4 (0.41) | IRAK4HIF1AFFAR1LPLLIPG | |
| SCHEMBL22650739 | 0.75 | IRAK4 (0.41) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL29425316 | 0.73 | IRAK4 (0.40) | IRAK4HIF1AFFAR1LPLLIPG | |
| SCHEMBL26352649 | 0.73 | IRAK4 (0.40) | IRAK4HIF1AFFAR1 | |
| SCHEMBL25335146 | 0.72 | TGFBR1 (0.44) | IRAK4 | |
| SCHEMBL22650905 | 0.71 | PIK3CA (0.47) | CAMKK1CAMKK2PIK3CACREBBP | |
| SCHEMBL31383607 | 0.71 | PIK3CA (0.36) | IRAK4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | IRAK4 2748/4885HIF1A 2015/4885CAMKK1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.